Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Pegylated (40kDa) Interferon Alfa-2a (PEGASYS) in Combination with Ribavirin , Mycophenolate Mofetil, Amantadine, or Amantadine plus Ribavirin in Patients that did not Respond to Rebetron Therapy: A Preliminary Report of a Randomized , Multicenter Study

Pegylated (40kDa) Interferon Alfa-2a (PEGASYS) in Combination with Ribavirin , Mycophenolate Mofetil, Amantadine, or Amantadine plus Ribavirin in Patients that did not Respond to Rebetron Therapy: A Preliminary Report of a Randomized , Multicenter Study. Digestive Disease Week Presentation in Atlanta, Ga. 2001.


© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.